Predicting the efficacy of variant-modified COVID-19 vaccine boosters-Reference-Cited by-同舟云学术

Predicting the efficacy of variant-modified COVID-19 vaccine boosters

Published:2022-08-26 Issue: Volume: Page:
ISSN:
Container-title:
language:
Short-container-title:

Author:

Khoury David S.^ORCID,Docken Steffen S.^ORCID,Subbarao Kanta,Kent Stephen J.^ORCID,Davenport Miles P.^ORCID,Cromer Deborah^ORCID

Abstract

AbstractAs a result of the emergence and circulation of antigenically distinct SARS-CoV-2 variants, a number of variant-modified COVID-19 vaccines have been developed. Here we perform a meta-analysis of the available data on neutralisation titres from clinical studies comparing booster vaccination with either the current ancestral-based vaccines or variant-modified vaccines. We then use this to predict the relative efficacies of these booster vaccines under different scenarios.

Publisher

Cold Spring Harbor Laboratory

Reference15 articles.

1. Immunogenicity and Safety of Beta-Adjuvanted Recombinant Booster Vaccine;N Engl J Med,2022

2. Branche AR , Rouphael NG , Diemert DJ , et al. SARS-CoV-2 Variant Vaccine Boosters Trial: Preliminary Analyses. medRxiv 2022.

3. Chalkias S , Eder F , Essink B , et al. Safety, Immunogenicity and Antibody Persistence of a Bivalent Beta-Containing Booster Vaccine. Research Square 2022.

4. Chalkias S , Harper C , Vrbicky K , et al. A Bivalent Omicron-containing Booster Vaccine Against Covid-19. medRxiv 2022: 2022.06.24.22276703.

5. Moderna’s Omicron-Containing Bivalent Booster Candidate, mRNA-1273.214, Demonstrates Significantly Higher Neutralizing Antibody Response Against Omicron Subvariants BA.4/5 Compared To Currently Authorized Booster (Moderna Press Release, 11 July, 2022). https://www.accesswire.com/708109/Modernas-Omicron-Containing-Bivalent-Booster-Candidate-mRNA-1273214-Demonstrates-Significantly-Higher-Neutralizing-Antibody-Response-Against-Omicron-Subvariants-BA45-Compared-To-Currently-Authorized-Booster

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antibody response to symptomatic infection with SARS-CoV-2 Omicron variant viruses, December 2021—June 2022;2023-11-18

2. Anti-SARS-CoV-2 Antibody Levels Associated with COVID-19 Protection in Outpatients Tested for SARS-CoV-2, US Flu VE Network, October 2021–June 2022;2023-09-23

3. ESCRT recruitment to SARS-CoV-2 spike induces virus-like particles that improve mRNA vaccines;Cell;2023-05

4. Immune Imprinting and Implications for COVID-19;Vaccines;2023-04-20

5. Impact of hybrid immunity booster vaccination and Omicron breakthrough infection on SARS-CoV-2 VOCs cross-neutralization;iScience;2023-04